Core Viewpoint - The recent antitrust penalties against three pharmaceutical companies in China highlight the exploitation of market concentration to inflate drug prices, particularly during the COVID-19 pandemic, raising concerns about unethical practices in the industry [1][7]. Group 1: Antitrust Case Details - Tianjin Municipal Market Supervision Administration imposed a total fine of 326 million yuan on Tianjin Pharmaceutical, Jiangsu Lianhuan Pharmaceutical, and Xianju Pharmaceutical for colluding to manipulate the price of Dexamethasone Sodium Phosphate [1][7]. - The price of Dexamethasone Sodium Phosphate surged from approximately 7,900 yuan per kilogram in November 2021 to 45,000 yuan per kilogram by November 2023, indicating a significant price manipulation [1][5]. Group 2: Market Dynamics - The concentration of market competition is a key factor enabling these companies to control raw material and formulation prices, with the three companies holding four out of eight approved production licenses for Dexamethasone Sodium Phosphate [3][4]. - The demand for Dexamethasone Sodium Phosphate injections increased significantly during the pandemic, allowing companies to profit even as costs rose, leading to further price hikes [4][5]. Group 3: Regulatory Environment - The Chinese government has adopted a "zero tolerance" approach towards monopolistic behaviors in the pharmaceutical sector, as evidenced by the total fines of 1.772 billion yuan for antitrust cases in 2023 [7]. - The ongoing normalization of national medical insurance procurement and the enhancement of antitrust regulatory frameworks are expected to reduce the gray areas of vertical monopolies in the pharmaceutical industry [7].

本报告由华创证券有限责任公司编制 www.hczq.com 证券研究报告 | 医药生物 | 2025年5月4日 卖的出价或询价。本报告所载信息均为个人观点，并不构成对所涉及证券的个人投资建议。 请仔细阅读PPT后部分的分析师声明及免责声明。 华创医药投资观点&研究专题周周谈 · 第124期 医药行业2024年报及2025年一季报业绩综述 华创医药团队： 首席分析师 郑辰 联席首席分析师 刘浩 医疗器械组组长 李婵娟 中药和流通组组长 高初蕾 分析师 王宏雨 分析师 朱珂琛 执业编号：S0360520110002 邮箱：zhengchen@hcyjs.com 执业编号：S0360520120002 邮箱：liuhao@hcyjs.com 执业编号：S0360520110004 邮箱：lichanjuan@hcyjs.com 执业编号：S0360524070002 邮箱：gaochulei@hcyjs.com 执业编号：S0360523080006 邮箱：wanghongyu@hcyjs.com 执业编号：S0360524070007 邮箱：zhukechen@hcyjs.com @2021 华创 版权所有 第一 ...

华夏时报（www.chinatimes.net.cn）记者 于娜 北京报道 当前，生物医药行业转型升级开始加速，从药品仿制迈向源头创新，实现从"跟跑"到"并跑"乃至"领跑"的跨越， 生物医药行业已成为驱动经济增长与科技创新的重要引擎。 毕马威中国近日携手海南国际医药创新联合基金会、苏州生物医药产业园，在北京、苏州、深圳三地线上线下联 动举办了"毕马威中国第三届生物科创领航50企业榜单发布暨颁奖典礼"，对中国生物科技产业创新韧性与发展潜 力作出深度注解。 目前，中国生物医药企业国际化步伐加快，研发管线规模不断增长，跨境交易日益频繁，License—out（企业技 术、专利等通过许可输出）和Newco（一种资产交易模式）等模式助力企业提升全球化竞争力。 据业内不完全统计，2025年一季度国内创新药企的出海表现令人瞩目，达成33笔交易，已披露金额超362亿美元。 其中，第一季度中ADC为出海主力，有8笔交易，已披露金额达165.27亿美元。 而4月，双抗为出海主力，5笔交 易中有3笔为双抗。 "当下，全球产业链格局加速调整，国际经贸规则面临深刻变革，而中国生物科技行业展现出强劲的逆周期韧性， 成为全球创新版图中的重 ...

美国总统特朗普：礼来制药的CEO一直向我谈起医药行业的"中间人"。 ...

□是 √否 一、 主要财务数据 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600436 证券简称：片仔癀 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏，并承担法律责任。 公司负责人林志辉、主管会计工作负责人杨海鹏及会计机构负责人（会计主管人员）郑志平 保证季度 报告中财务信息的真实、准确、完整。 第一季度财务报表是否经审计 (一) 主要会计数据和财务指标 单位：元 币种：人民币 (二) 非经常性损益项目和金额 √适用 □不适用 单位:元 币种:人民币 对公司将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》未列举的项目认定为非 经常性损益项目且金额重大的，以及将《公开发行证券的公司信息披露解释性公告第1号——非经常性 损益》中列举的非经常性损益项目界定为经常性损益的项目，应说明原因。 √适用 □不适用 单位：元 币种：人民币 (三) 主要会计数据、财务指标发生变 ...

证券代码：600436 证券简称：片仔癀 公告编号：2025-014 漳州片仔癀药业股份有限公司 根据《上海证券交易所上市公司自律监管指引第3号——行业信息披 露》（2022年修订）《上市公司行业信息披露指引第六号——医药制造》 （2022年修订）等相关法律法规，漳州片仔癀药业股份有限公司（以下简 称"公司"）现将2025年第一季度主要经营数据披露如下： 一、 公司 2025 年第一季度主营业务分行业情况 1 / 4 单位：万元 人民币 行业 主营业务 收入 主营业务 成本 毛利率 （%） 主营业务 收入增长 率（%） 主营业务 成本增长 率（%） 毛利率增 减情况 医药 制造业 187,387.69 70,765.30 62.24 13.31 44.95 减少8.24 个百分点 医药 流通业 101,395.09 90,529.53 10.72 -19.11 -15.38 减少3.93 个百分点 医药行 业小计 288,782.78 161,294.83 44.15 -0.67 3.52 减少2.26 个百分点 化妆品业 19,724.96 6,440.66 67.35 -1.17 1.68 减少0.91 ...

Core Viewpoint - The company reported a significant decline in performance for 2024, with a revenue of 2.467 billion yuan, down 5.48% year-on-year, and a net loss of 299 million yuan, marking a drastic shift from a profit of 263 million yuan in the previous year [1][4][10] Revenue and Profitability - The company's revenue has been on a downward trend since 2022, with figures of 2.676 billion yuan in 2022, 2.611 billion yuan in 2023, and 2.467 billion yuan in 2024 [2] - The traditional Chinese medicine segment generated 1.318 billion yuan, accounting for 53.93% of total revenue, while chemical drugs contributed 899 million yuan, or 36.81% [2] - The average price of the core product, Compound XueShuanTong series, dropped by 52% after entering national procurement, leading to a revenue decrease of approximately 120 million yuan despite an 18% increase in sales volume [3] Business Segments - The company is undergoing a transformation from traditional Chinese medicine to an innovative pharmaceutical company, focusing on three main business areas: traditional Chinese medicine, chemical drugs, and innovative drugs [1][10] - The chemical generic drug sector is being refined, with six products approved in 2024, while the raw materials and intermediates segment saw a revenue drop of 26.98% to 30.49 million yuan [3][5] R&D and Innovation - The company has a strong commitment to R&D, with a research expense ratio of 10.68% in 2024, despite a decrease from 12.5% in 2023 [8] - The company has halted several clinical projects, resulting in a one-time impairment loss of 207 million yuan, reflecting a focus on core pipelines [8][9] - The innovative drug RAY1225 is projected to generate significant sales in the diabetes and obesity management market, with estimated contributions of 1.369 billion yuan for diabetes and 700 million yuan for weight management by 2033 [9] Asset Management and Impairment - The company recorded an asset impairment loss of 547 million yuan in 2024, primarily due to goodwill impairment related to subsidiaries and R&D projects [6][7] - The goodwill value at the end of 2024 was 318 million yuan, significantly reduced from 530 million yuan in 2023, indicating challenges in integrating acquired assets [6][7] Market Position and Future Outlook - The company is positioned in a critical transition phase, aiming to redefine its industry status and enhance its innovative capabilities [1][10] - The next 2-3 years are crucial for the company to validate its innovative drug commercialization capabilities, with potential risks if core projects face obstacles [10]

Core Insights - The Chinese pharmaceutical industry is undergoing significant transformation due to policies like "Two Invoice System" and "Volume-based Procurement," leading to compressed profit margins [1] - The average gross margin in China's pharmaceutical distribution industry fell to 7.2% in 2022, down from 9.8% in 2018, indicating a need for digital transformation [1] - The B2B private domain mall solution by Shushangyun aims to help pharmaceutical companies transition from traditional distribution models to digital marketing, having served over 300 companies with an average online transaction growth of 150% and an 80% increase in marketing efficiency [1] Market Status and Pain Points - The Chinese B2B pharmaceutical e-commerce market reached 256 billion yuan in 2022 and is expected to exceed 500 billion yuan by 2025, with a compound annual growth rate of over 25% [3] - Key drivers of this growth include regulatory support, the impact of the pandemic accelerating online processes, and technological advancements like AI and big data [3] - Pharmaceutical companies face four main pain points: high traditional channel costs (20-30% of distribution costs), low marketing efficiency (average cost of 500 yuan per sales visit), severe data silos (over 80% of companies), and increasing compliance risks [3] Solution Architecture - The B2B private domain mall solution features a "four-layer three-end" architecture, including a hybrid cloud infrastructure, data middle platform, business middle platform, and application layer [4] - Core functionalities include intelligent product management, unified order management across multiple channels, precise marketing systems, professional pharmaceutical services, supply chain collaboration, and a data dashboard for business insights [4][6] Case Studies - A top 20 pharmaceutical company with over 5 billion yuan in annual sales improved its marketing efficiency and reduced customer churn through the implementation of a digital marketing system [5] - A regional leading commercial company serving over 3,000 terminals enhanced its supply chain efficiency and reduced order processing time significantly by adopting intelligent supply chain systems [5][6] Future Trends - The industry is expected to see innovation driven by technology, including deep AI applications, blockchain for drug traceability, and digital twins for supply chain optimization [7] - The business model is evolving from transaction platforms to service platforms, focusing on building an industrial internet ecosystem and monetizing data value [7] Why Choose Shushangyun - Shushangyun has extensive industry experience, having served over 300 pharmaceutical companies, and offers over 50 specialized functions for the pharmaceutical sector [7] - The company provides efficient implementation with standard solutions that can be launched in two months and offers 24/7 operational support [7]

Core Viewpoint - In 2024, Taimei Medical Technology (02576.HK) reported mixed results amid a cooling medical SaaS market, with revenue declining by 3.8% year-on-year to 551 million RMB, and a net loss of 217 million RMB, although the adjusted loss narrowed to 57.26 million RMB, continuing its trend of losses since 2018 [1][3]. Financial Performance - The company has experienced a cumulative loss exceeding 1.2 billion RMB over the past three years, with net losses of 480 million RMB, 413 million RMB, and 347 million RMB from 2021 to 2023 [2]. - Employee count was significantly reduced from 1,492 in 2021 to 627 by the end of 2024, leading to a decrease in employee costs by 59.2 million RMB and a nearly 40% reduction in employee benefits to 364 million RMB [3][4]. - Despite cost-cutting measures, the total expenses for sales, R&D, and administration still accounted for 90% of revenue [4]. Revenue Breakdown - The company's revenue from digital services fell by 7.4% to 343 million RMB in 2024, attributed to intensified market competition and declining average service prices [6]. - The core IRC business saw its average price drop by 70% over three and a half years, with revenues of 89.98 million RMB, 101 million RMB, and 89.83 million RMB from 2021 to 2023, while its gross margin decreased from 50.8% to 42.3% [5][7]. - Revenue from cloud software, primarily from SaaS products, showed a slight increase of 4% in 2024, but overall revenue from mainland China decreased by 8.1% to 522 million RMB [6][8]. Market Challenges - The digital services sector faces challenges in establishing a sustainable pricing model and achieving low-cost, high-margin growth due to the inability to meet critical industry needs [8].

证券研究报告|医药生物|2025年3月29日 www.hczq.com 华创医药投资观点&研究专题周周谈·第119期 2025Q1医药业绩前瞻 本报告由华创证券有限责任公司编制 报告仅供华创证券有限责任公司的客户使用，本公司不会因按久收到本报告而预其为客户。华创证券的这些信息的准确性和完整性不作任何保证，报告中的内容和赏见仅体参考，并不构成本公司对所述证券买 卖的出价或狗价，本报告所载信息均为个人观点，并不构成对所涉及证券的个人投资建议。 :请仔细阅读PPT后部分的分析师声明及免责声明。 ER | 01 | 行情回顾 | | --- | --- | | 02 | 板块观点和投资组合 | | 03 | 行业和个股事件 | 本周行情回顾 = 华创研究 本周中信一级行业指数涨跌幅 09 -1% -25 -3% -4% -5% -69 | 华创医药团队： | | | --- | --- | | 首席分析师 郑辰 | 执业编号: S0360520110002 邮箱: zhengchen@hcyjs.com | | 联席首席分析师 刘浩 | 执业编号: S0360520120002 邮箱: liuhao@hcyjs.co ...